Silvia Novello Giorgio Scagliotti Peter Goodwin interviews Silvia Novello, and Giorgio Scagliotti from the University of Turin about harnessing insulin-like growth factor receptor inhibition in a phas
Silvia Novello
Giorgio Scagliotti
Peter Goodwin interviews Silvia Novello, and Giorgio Scagliotti from the University of Turin about harnessing insulin-like growth factor receptor inhibition in a phase II study which has shown clinical activity of figitumumab at least as significant as inhibitors of other growth factors already being used in cancer.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090323OTBNpart1.mp3]